3.86
price down icon2.81%   -0.1117
after-market Handel nachbörslich: 3.86
loading
Schlusskurs vom Vortag:
$3.9717
Offen:
$4.0797
24-Stunden-Volumen:
9,169
Relative Volume:
0.42
Marktkapitalisierung:
$21.57M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.29M
KGV:
-0.698
EPS:
-5.53
Netto-Cashflow:
$-12.27M
1W Leistung:
-9.18%
1M Leistung:
+48.46%
6M Leistung:
-27.85%
1J Leistung:
-3.50%
1-Tages-Spanne:
Value
$3.85
$4.0797
1-Wochen-Bereich:
Value
$3.82
$4.42
52-Wochen-Spanne:
Value
$2.1501
$8.8465

Aprea Therapeutics Inc Stock (APRE) Company Profile

Name
Firmenname
Aprea Therapeutics Inc
Name
Telefon
617-463-9385
Name
Adresse
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Name
Mitarbeiter
7
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
APRE's Discussions on Twitter

Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2020-12-28 Herabstufung Robert W. Baird Outperform → Neutral
2020-12-16 Eingeleitet Berenberg Buy
2020-09-29 Fortgesetzt JP Morgan Neutral
2020-06-22 Eingeleitet H.C. Wainwright Neutral
2020-04-21 Eingeleitet Robert W. Baird Outperform
2019-10-28 Eingeleitet JP Morgan Neutral
2019-10-28 Eingeleitet Morgan Stanley Equal-Weight
2019-10-28 Eingeleitet RBC Capital Mkts Outperform
Alle ansehen

Aprea Therapeutics Inc Aktie (APRE) Neueste Nachrichten

pulisher
Oct 31, 2024

Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MyChesCo

Oct 31, 2024
pulisher
Oct 29, 2024

Aprea Therapeutics Presents Promising Safety Data for WEE1 Inhibitor at International Symposium - MSN

Oct 29, 2024
pulisher
Oct 28, 2024

DDR Defective Tumors Market Growth Surge: Key Players and Market - openPR

Oct 28, 2024
pulisher
Oct 27, 2024

Can Aprea Therapeutics (APRE) Spring Back This Year? - RTTNews

Oct 27, 2024
pulisher
Oct 26, 2024

Aprea therapeutics director sells shares worth $29,583 By Investing.com - Investing.com South Africa

Oct 26, 2024
pulisher
Oct 26, 2024

Aprea Therapeutics (NASDAQ:APRE) Rating Reiterated by HC Wainwright - Defense World

Oct 26, 2024
pulisher
Oct 25, 2024

Aprea therapeutics director sells shares worth $29,583 - Investing.com India

Oct 25, 2024
pulisher
Oct 24, 2024

Aprea therapeutics CEO Gilad Oren buys $1,957 in stock - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

Aprea Therapeutics presents preliminary results on APR-1051 - Yahoo Finance

Oct 24, 2024
pulisher
Oct 24, 2024

Aprea therapeutics CEO Gilad Oren buys $1,957 in stock By Investing.com - Investing.com UK

Oct 24, 2024
pulisher
Oct 23, 2024

Insider Spends US$132k Buying More Shares In Aprea Therapeutics - Yahoo Finance

Oct 23, 2024
pulisher
Oct 23, 2024

Aprea Therapeutics falls on data from APR-1051 study in cancer-associated gene alterations - Seeking Alpha

Oct 23, 2024
pulisher
Oct 23, 2024

Aprea reports safe trial results for new cancer drug - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

Aprea reports safe trial results for new cancer drug By Investing.com - Investing.com UK

Oct 23, 2024
pulisher
Oct 23, 2024

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics - The Manila Times

Oct 23, 2024
pulisher
Oct 23, 2024

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR - EIN News

Oct 23, 2024
pulisher
Oct 20, 2024

Positive Signs As Multiple Insiders Buy Aprea Therapeutics Stock - Simply Wall St

Oct 20, 2024
pulisher
Oct 17, 2024

Aprea therapeutics director Duey Marc acquires $131,700 in stock By Investing.com - Investing.com South Africa

Oct 17, 2024
pulisher
Oct 17, 2024

Aprea therapeutics director Duey Marc acquires $131,700 in stock - Investing.com India

Oct 17, 2024
pulisher
Oct 17, 2024

Aprea Therapeutics CEO Gilad Oren buys $725 in common stock By Investing.com - Investing.com South Africa

Oct 17, 2024
pulisher
Oct 17, 2024

Aprea therapeutics CFO John Hamill acquires shares worth $123 - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

Aprea Therapeutics CEO Gilad Oren buys $725 in common stock - Investing.com India

Oct 17, 2024
pulisher
Oct 16, 2024

Aprea Therapeutics director Duey Marc buys $490 in stock - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Aprea therapeutics CFO John Hamill acquires shares worth $123 By Investing.com - Investing.com South Africa

Oct 16, 2024
pulisher
Oct 16, 2024

Aprea Therapeutics director Duey Marc buys $490 in stock By Investing.com - Investing.com South Africa

Oct 16, 2024
pulisher
Oct 16, 2024

Aprea therapeutics director Bernd Seizinger buys $26,800 in stock By Investing.com - Investing.com Australia

Oct 16, 2024
pulisher
Oct 16, 2024

Aprea Therapeutics president Gilad Oren buys $2,971 in stock - Investing.com India

Oct 16, 2024
pulisher
Oct 15, 2024

Aprea Therapeutics to Showcase Expertise at Maxim Healthcare Virtual Summit - MyChesCo

Oct 15, 2024
pulisher
Oct 15, 2024

Aprea therapeutics CFO John Hamill buys $1,174 in common stock By Investing.com - Investing.com South Africa

Oct 15, 2024
pulisher
Oct 15, 2024

Aprea therapeutics director Bernd Seizinger buys $26,800 in stock - Investing.com India

Oct 15, 2024
pulisher
Oct 15, 2024

Aprea Therapeutics president Gilad Oren buys $2,971 in stock By Investing.com - Investing.com Canada

Oct 15, 2024
pulisher
Oct 15, 2024

Director Bernd Seizinger Acquires 10,000 Shares of Aprea Therape - GuruFocus.com

Oct 15, 2024
pulisher
Oct 14, 2024

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit - ForexTV.com

Oct 14, 2024
pulisher
Oct 11, 2024

Aprea Therapeutics to Showcase Oncology Advances at Barcelona Symposium - MyChesCo

Oct 11, 2024
pulisher
Oct 10, 2024

Stonepine Capital Management, LLC Increases Stake in Aprea Therapeutics Inc - Yahoo Finance

Oct 10, 2024
pulisher
Oct 10, 2024

Stonepine Capital Management, LLC Increases Stake in Aprea Thera - GuruFocus.com

Oct 10, 2024
pulisher
Oct 10, 2024

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics - ForexTV.com

Oct 10, 2024
pulisher
Oct 10, 2024

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and - EIN News

Oct 10, 2024
pulisher
Oct 10, 2024

Aprea Therapeutics Welcomes Dr. Philippe Pultar as Senior Medical Advisor - MyChesCo

Oct 10, 2024
pulisher
Oct 10, 2024

Prelude Therapeutics Showcases Innovative SMARCA Degrader Programs at Barcelona Symposium - MyChesCo

Oct 10, 2024
pulisher
Oct 09, 2024

APRE stock touches 52-week low at $2.22 amid market challenges By Investing.com - Investing.com South Africa

Oct 09, 2024
pulisher
Oct 09, 2024

APRE stock touches 52-week low at $2.22 amid market challenges - Investing.com UK

Oct 09, 2024
pulisher
Oct 09, 2024

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development - The Manila Times

Oct 09, 2024
pulisher
Oct 08, 2024

Aprea Therapeutics to Present at Lytham Partners Fall Investor Conference - MSN

Oct 08, 2024
pulisher
Oct 01, 2024

Halda appoints new chief executive - The Pharma Letter

Oct 01, 2024
pulisher
Oct 01, 2024

Stonepine Capital Management LLC Acquires Shares of 137,174 Aprea Therapeutics, Inc. (NASDAQ:APRE) - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

Halda Therapeutics Appoints Christian Schade as CEO - citybiz

Oct 01, 2024

Finanzdaten der Aprea Therapeutics Inc-Aktie (APRE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):